Physician profile
Sunny Lo
NPI 1891053187
$6,471.08
in general payments reported to CMS, 2019-2025
24 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $295 · 2021: $234 · 2022: $394 · 2023: $924 · 2024: $2,296 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,228 · Travel and Lodging: $855 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,227.91 |
| Travel and Lodging | $855.01 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,599.28 | 2019-2025 | Overstitch Endoscopic Suturing System, Superion Indirect Decompression System |
| Ardelyx, INC. | $1,300.24 | 2022-2025 | Ibsrela |
| Abbvie INC. | $1,117.87 | 2019-2025 | |
| Janssen Biotech, INC. | $509.98 | 2024-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $497.39 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $255.51 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $242.17 | 2022-2025 | |
| Madrigal Pharmaceuticals | $209.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $208.22 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $96.27 | 2024-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $71.91 | 2022-2024 | Dificid |
| Pfizer INC. | $56.34 | 2025 | |
| Novo Nordisk INC | $44.66 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $37.57 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $36.65 | 2020-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $32.94 | 2021-2023 | Suflave |
| Conmed Corporation | $28.52 | 2025 | Conmed Biliary |
| Medtronic, INC. | $24.94 | 2025 | Progrip |
| Apollo Endosurgery US INC | $23.96 | 2022 | |
| Shionogi INC | $19.07 | 2019 | |
| Omega Medical Imaging, LLC | $18.63 | 2024 | |
| Vivus LLC | $14.45 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.78 | 2020 | |
| Allergan, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunny Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.